$2.87
4.36% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
IL0011313900
Symbol
GLMD
Sector
Industry

Galmed Pharmaceuticals Ltd. Stock price

$2.87
-1.06 26.97% 1M
-1.78 38.26% 6M
-2.59 47.44% YTD
-0.83 22.50% 1Y
-454.33 99.37% 3Y
-807.13 99.65% 5Y
-1,055.51 99.73% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.12 4.36%
ISIN
IL0011313900
Symbol
GLMD
Sector
Industry

Key metrics

Market capitalization $4.76m
Enterprise Value $-12.50m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 2.60
P/B ratio (TTM) P/B ratio 0.23
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-6.79m
Free Cash Flow (TTM) Free Cash Flow $-4.81m
Cash position $17.26m
EPS (TTM) EPS $-12.04
Short interest 3.08%
Show more

Is Galmed Pharmaceuticals Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Galmed Pharmaceuticals Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Galmed Pharmaceuticals Ltd.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Galmed Pharmaceuticals Ltd.:

Buy
100%

Financial data from Galmed Pharmaceuticals Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.09 0.09
200% 200%
-
-0.09 -0.09
-
-
- Selling and Administrative Expenses 3.58 3.58
9% 9%
-
- Research and Development Expense 3.03 3.03
21% 21%
-
-6.70 -6.70
14% 14%
-
- Depreciation and Amortization 0.09 0.09
-
-
EBIT (Operating Income) EBIT -6.79 -6.79
13% 13%
-
Net Profit -6.32 -6.32
16% 16%
-

In millions USD.

Don't miss a Thing! We will send you all news about Galmed Pharmaceuticals Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Galmed Pharmaceuticals Ltd. Stock News

Neutral
PRNewsWire
2 months ago
The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH) Data is confirmed using 3 objective measurements; NASH CRN, paired ranked reading, and Artificial Intelligence (AI) quantitative digital analysis Continuous histological fibrosis scores generated in antifibrotic trials by digital pathology ima...
Neutral
PRNewsWire
2 months ago
Aramchol is the most clinically advanced, first-in-class, Stearoyl-CoA desaturase1 (SCD1) oral inhibitor, demonstrating in Ph2 and Ph3 (open label part) an excellent safety profile with metabolic and anti-fibrotic effects. Galmed raised an aggregate of $7.5 million in warrant exercises and drawdowns on its recently adopted equity line TEL AVIV, Israel , Sept.
Positive
MarketBeat
2 months ago
Galmed Pharmaceuticals NASDAQ: GLMD, a little-known biotech stock, has become the center of attention as its shares have skyrocketed close to 400%. By 2 pm, the stock had traded over 80 million shares, a monumental leap from its average daily volume of just 75,000.

Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Head office Israel
CEO Allen Baharaff
Employees 8
Founded 2000
Website galmedpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today